A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours

BACKGROUND: This phase I, dose-finding study determined the safety, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D), pharmacokinetics, and antitumour activity of PX-866, a phosphatidylinositol 3-kinase inhibitor, combined with docetaxel in patients with incurable solid tumours. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Bowles, D W, Ma, W W, Senzer, N, Brahmer, J R, Adjei, A A, Davies, M, Lazar, A J, Vo, A, Peterson, S, Walker, L, Hausman, D, Rudin, C M, Jimeno, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778312/
https://www.ncbi.nlm.nih.gov/pubmed/23942080
http://dx.doi.org/10.1038/bjc.2013.474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778312/
https://www.ncbi.nlm.nih.gov/pubmed/23942080
http://dx.doi.org/10.1038/bjc.2013.474

Ejemplares similares